URB2 as an important marker for glioma prognosis and immunotherapy

Chaoyou Fang; Zeyu Zhang; Yongquan Han; Houshi Xu; Zhengyang Zhu; Yichao Du; Pinpin Hou; Ling Yuan; Anwen Shao; Anwen Shao; Anke Zhang; Anke Zhang; Meiqing Lou

doi:10.3389/fphar.2023.1113182

Frontiers in Pharmacology (Mar 2023)

URB2 as an important marker for glioma prognosis and immunotherapy

Chaoyou Fang,
Zeyu Zhang,
Yongquan Han,
Houshi Xu,
Zhengyang Zhu,
Yichao Du,
Pinpin Hou,
Ling Yuan,
Anwen Shao,
Anwen Shao,
Anke Zhang,
Anke Zhang,
Meiqing Lou

Affiliations

Chaoyou Fang: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Zeyu Zhang: Department of Neurosurgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Yongquan Han: Department of Neurosurgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
Houshi Xu: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Zhengyang Zhu: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yichao Du: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Pinpin Hou: Central Laboratory, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Ling Yuan: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Anwen Shao: Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Anwen Shao: Clinical Research Center for Neurological Diseases of Zhejiang Province, Hangzhou, China
Anke Zhang: Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Anke Zhang: Clinical Research Center for Neurological Diseases of Zhejiang Province, Hangzhou, China
Meiqing Lou: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

DOI: https://doi.org/10.3389/fphar.2023.1113182
Journal volume & issue: Vol. 14

Abstract

Read online

Introduction: Glioma is the most common primary brain tumor and primary malignant tumor of the brain in clinical practice. Conventional treatment has not significantly altered the prognosis of patients with glioma. As research into immunotherapy continues, glioma immunotherapy has shown great potential.Methods: The clinical data were acquired from the Chinese Glioma Genome Atlas (CGGA) database and validated by the Gene Expression Omnibus (GEO) database, The Cancer Genome Atlas (TCGA) dataset, Clinical Proteomic Tumor Analysis Consortium (CPTAP) database, and Western blot (WB) analysis. By Cox regression analyses, we examined the association between different variables and overall survival (OS) and its potential as an independent prognostic factor. By constructing a nomogram that incorporates both clinicopathological variables and the expression of URB2, we provide a model for the prediction of prognosis. Moreover, we explored the relationship between immunity and URB2 and elucidated its underlying mechanism of action.Results: Our study shows that URB2 likely plays an oncogenic role in glioma and confirms that URB2 is a prognostic independent risk factor for glioma. Furthermore, we revealed a close relationship between immunity and URB2, which suggests a new approach for the immunotherapy of glioma.Conclusion: URB2 can be used for prognosis prediction and immunotherapy of glioma.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords